论文部分内容阅读
目的探究亚段性肝动脉介入化疗栓塞联合华蟾素治疗中晚期肝癌的临床疗效。方法选择中晚期肝癌患者47例,根据治疗情况分为STACE组和TACE组;两组病人术后均随机分为华蟾素联合治疗组和对照组。于治疗前后检查血常规、AFP、肝肾功能。疗程结束测量病灶大小,生活质量根据Kannofsky评分标准,并进行生存率评估。结果蟾素联合治疗组在阻止肿瘤进展(21/24vs14/23),稳定生活质量(20/24vs13/23),及减少化疗造成的白细胞减少(3/24vs11/23)及肝功能恶化方面与对照组比较有明显的优越性,与STACE联合治疗在生存率(12个月8/12vs2/12;18个月4/12vs0/12)上亦明显的优于单纯采用TACE治疗。STACE治疗在瘤体的缩小(14/23vs8/24)、生活质量的提高(10/23vs4/24)、术后肝功的影响、生存期(13.3个月vs9.1个月)等各个方面均优于TACE治疗。尤其是华蟾素联合STACE治疗在提高疗效、提高生存质量、延长生存期、减少化疗副作用等方面更是大大优于单纯TACE治疗。结论华蟾素联合STACE治疗在提高疗效、提高生存质量、延长生存期、减少化疗副作用等方面大大优于单纯TACE治疗,可以作为治疗中晚期肝癌的有效方法得到更广泛的普及。
Objective To investigate the clinical efficacy of sub-regional hepatic arterial chemoembolization combined with cinobufacini in the treatment of advanced hepatocellular carcinoma. Methods Forty-seven patients with advanced hepatocellular carcinoma (HCC) were enrolled in this study. They were divided into STACE group and TACE group according to the treatment. Both groups were randomly divided into cinobufacini combined group and control group. Before and after treatment check blood, AFP, liver and kidney function. At the end of the treatment, the size of the lesion and the quality of life were measured according to the Kannofsky score and the survival rate was evaluated. Results Compared with the control group, the cinobufotalin treatment group showed no significant effect on tumor progression (21/24 vs 14/23), stable quality of life (20/24 vs 13/23), and chemotherapy-induced leukopenia (3/24 vs 11/23) and liver function deterioration Compared with STACE, the combination therapy was superior to TACE in the survival rate (12 months 8 / 12vs2 / 12; 18 / 12vs0 / 12). The reduction of STACE (14/23 vs 8/24), improvement of quality of life (10/23 vs 4/24), postoperative liver function, survival (13.3 months vs9.1 months) and other aspects Better than TACE treatment. In particular, cinobufacini combined STACE treatment is much better than simple TACE in improving efficacy, improving quality of life, prolonging survival and reducing the side effects of chemotherapy. Conclusions Cinobufacini combined with STACE treatment is superior to simple TACE treatment in improving the curative effect, improving the quality of life, prolonging the survival period and reducing the side effects of chemotherapy. It can be widely used as an effective method for the treatment of advanced liver cancer.